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ABSTRACT
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Signaling mechanisms linking SAMHD1-deficiency to the 
type I interferonopathy
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SAMHD1 is an enzyme which has dual enzymatic activities: deoxynucleoside 
triphosphohydrolase (dNTPase) and phosphorolytic 3′-5′ exoribonuclease. 
Even though SAMHD1 was identified initially as the human ortholog of the 
mouse IFNg-induced gene Mg11, studies about SAMHD1 have focused 
overwhelmingly on the inhibitory mechanism of SAMHD1 against HIV-1 
replication. SAMHD1 was demonstrated to restrict HIV-1 replication by 
reducing cellular dNTP concentrations below the levels required for retroviral 
reverse transcription in dNTPase dependent manner. In addition, it is also 
suggested that SAMHD1 can bind to and degrade HIV-1 RNA to restrict the 
replication of HIV-1 through the RNase activity.
A disturbance of the type I interferon homeostasis is central to the 
pathogenesis of the autoimmune diseases. The autoimmune disorder Aicardi-
Goutières syndrome (AGS) is characterized by a constitutive type I interferon 
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response clinically overlapping with congenital infection and systemic lupus 
erythematosus (SLE). All the genes that are mutated in patients with AGS 
encode enzymes (TREX1, RNASEH2, ADAR, SAMHD and IFIH1) that are 
associated with nucleic acid metabolism, leading to the hypothesis that the 
inappropriate accumulation of endogenous nucleic acid species resulting from 
the dysfunction of AGS-related enzymes triggers the chronic type I interferon 
response. The mechanisms by which malfunctions of TREX1, RNASEH2, 
ADAR1 and IFIH1 occur AGS are considerably investigated and suggested. 
However, how SAMHD1-deficiency causes the type I interferon response in 
patients with AGS remains unknown, even though mutations in SAMHD1
cause AGS. In addition, Samhd1-deficient mice did not exhibit any distinct 
clinical phenotypes. Therefore, it is very important to identify the mechanism by 
which SAMHD1-deficiency results in AGS in human patients. 
Here, I generated SAMHD1-deficient THP-1 cell lines and showed that those 
cell lines recapitulate AGS phenotypes which include the activation of type I 
interferon response and delayed cell cycle progression. I further showed that 
SAMHD1 proteins purified from undifferentiated THP-1 cells possessed RNase 
activity. Then, RNA derived from SAMHD1-deficient cells, but not that from 
wild-type cells neither DNA derived from wild-type and SAMHD1-deficient cells, 
significantly activated IFN-α expression. In addition, the reconstitution of wild-
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type SAMHD1 and SAMHD1D137N, which possess RNase activity, only 
repressed the IFN-a induction in SAMHD1-deficient cells. These results 
suggest that cytosolic RNA species accumulated in the absence of SAMHD1 
act as a major immunogenic source for the type I interferon response. I also 
proposed that innate sensing of the endogenous retroelements-derived 
transcripts accumulated in SAMHD1-deficient cells results in significant type I 
interferon response and this accounts for the cause of SAMHD1-related AGS. 
This was supported with my data showing significant portion of the 
retroelement RNAs identified in SAMHD1 CLIP-seq and upregulated in 
SAMHD1-deficient cells. Even though many nucleic acid sensing pathways 
were already identified, this IFN signature occurred independently of all 
previously known nucleic acid sensing pathways that ultimately converge on 
activation of TBK1. Only IRF3 was indispensable for the spontaneous IFN 
signature in SAMHD1-deficient cells. Therefore, I sought to identify the RNA 
sensing pathway associated with ISG induction in SAMHD1-deficient cells and 
showed that the PI3K/AKT/IRF3 signaling pathway is essential for the type I 
interferon response in SAMHD1-deficient THP-1 cells. AKT and IRF3 were 
highly activated in SAMHD1-deficient cells, as assessed by the 
phosphorylation levels of these molecules. Then, treatment of PI3K or AKT 
inhibitors dramatically reduced the type I interferon signatures in SAMHD1-
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deficient cells. Moreover, SAMHD1/AKT1 double knockout relieved the type I 
interferon signatures to the levels observed in wild-type cells. The 
reconstitution of wild-type SAMHD1 and SAMHD1D137N inhibited the activation 
of AKT in SAMHD1-deficient cells, showing that RNase activity of SAMHD1 is 
critical for AKT activation as well as spontaneous IFN response. In human 
PBMCs, siRNA-mediated SAMHD1 silencing recapitulated the phenotypes 
seen in SAMHD1-deficient THP-1 cells. By comparison, knockout of SAMHD1
in not only HEK293T and HeLa cells but also PMA-differentiated THP-1 cells 
did not result in the activation of STAT1 or the induction of ISGs, suggesting 
that the type I interferonopathy associated with SAMHD1-deficiency is cell 
type-specific. My data provide an insight not only into the pathogenesis of the 
type I interferonopathies but also will encourage the development and use of
immunosuppressive therapies in AGS and related autoimmune diseases.




1. Characteristics of SAMHD1 protein
SAMHD1 is an antiviral protein that is highly expressed in cells of the myeloid 
lineage (1, 2). SAMHD1 was identified initially as the human ortholog of the 
IFNγ-induced gene Mg11 (3). SAMHD1 consists of N-terminal sterile alpha 
motif (SAM) domain and C-terminal HD domain. Of the two domains, the 
former is expected to be involved in protein-protein or protein-RNA interaction
(4). The latter is a characteristic of an enzyme family with phosphodiesterase 
or nuclease activity (5). The experiments using purified recombinant SAMHD1 
proteins demonstrated that SAMHD1 has dGTP-activated deoxynucleoside 
triphosphohydrolase (dNTPase) activity which cleaves the triphosphate from 
deoxynucleoside triphosphate (6-8). Recently, it has been reported that 
dNTPase activity of SAMHD1 is affected by the phosphorylation or the 
acetylation status of SAMHD1 (9-11). Moreover, phosphorolytic 3′-5′ 
exoribonuclease activity of SAMHD1 that degrades single-stranded RNA was 
also identified (12, 13). 
The wild-type SAMHD1 is mainly detected in the nucleus, because SAMHD1 
possesses a classical nuclear localization signal (NLS) (14, 15). However, 
SAMHD1 is also found in the cytoplasm (16) and the mutagenesis of NLS 
8
causes the change in the cellular localizaion of SAMHD1 from the nucleus to 
the cytoplasm.
9
Figure 1. Schematic illustration of SAMHD1 protein and its functional 
domains
SAMHD1 is a 626 amino acid protein which has an SAM and HD domain. NLS 
located in N-terminus, a critical region which is responsible for Vps interaction 
and four residues in HD domain are indicated. Numbers denote the position of 
amino acids in SAMHD1 protein.
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2. SAMHD1-mediated retroviral restriction
The concentration of dNTP pools in mammalian cells are tightly regulated and 
differ depending on cell types, differentiation state and cell cycle (17). It is 
known that intracellular nucleotides can control retroviral infections through the 
regulation of DNA synthesis by reverse transcriptases (RT) (18). Even though 
lentiviral RTs such as HIV-1 and SIV can be functional at the low dNTP 
concentrations compared with retroviral RTs (19, 20), HIV-1 can rarely infect 
quiescent cells that have severely decreased dNTP pools (7, 21). It is also 
indicated that the Vpx, an accessary protein of SIV and HIV-2, mediated 
degradation of SAMHD1 can enhance the infectivity of HIV-1 in human DCs 
and macrophages (1, 2, 22, 23). These results led to the hypothesis that 
SAMHD1 suppresses HIV-1 replication by depleting the intracellular dNTP 
pools. Many studies demonstrated that SAMHD1 lowers the concentration of 
intracellular dNTPs below the levels to support reverse transcription (1, 2, 6, 7, 
24, 25). On the contrary, Vpx-meidated SAMHD1 degradation significantly 
increased dNTP concentration and Vpx counteracted the SAMHD1-mediated 
HIV-1 restriction in myeloid cells (26). These studies indicate the strong inverse 
correlation between SAMHD1 expression and nNTP concentration/HIV-1
11
replication. However, the addition of dN into resting CD4+ T cells could not 
completely restore HIV-1 infectivity, even though it significantly increased the 
intracellular dNTP concentration (16). Furthermore, the phosphorylation of 
SAMHD1 at Thr-592 negatively regulated the HIV-1 restriction function of 
SAMHD1 without any changes in the cellular dNTP levels (27, 28). Thus, it is 
suggested that an additional cellular function of SAMHD1 may be involved in
SAMHD1-mediated HIV-1 restriction.
Recent studies reported that SAMHD1 functions as a 3ʹ-5ʹ exonuclease 
degrading ssRNA or ssDNA in vitro (12, 29). Those also demonstrated that 
SAMHD1 can bind to and degrade HIV-1 RNA, suggesting the novel 
mechanism of SAMHD1 restricting the replication of HIV-1 and retroviruses. 
However, several studies reported that they did not observe the RNase activity 




Figure 2. SAMHD1-mediated restriction to HIV-1
After viral entry, viral genomic RNA is released into the cytoplasm and reverse 
transcribed in a linear dsDNA. SAMHD1 possesses both dNTPase and RNase 
activity. SAMHD1 can function as a dNTPase to decrease the levels of DNA 
building block, dNTPs and subsequently inhibit the reverse transcription of 
HIV-1. In addition, SAMHD1 can directly bind and degrade HIV-1 genomic 
RNA to restrict the replication of HIV-1.
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3. SAMHD1 and Aicardi-Goutières syndrome
Although studies have focused overwhelmingly on the inhibitory mechanism of 
SAMHD1 against HIV-1 replication because of an unexpected identification of 
SAMHD1 as an HIV-1 restriction factor, SAMHD1 has been proposed to serve 
as a negative regulator of the innate immune response (32). It has been 
reported that mutations in SAMHD1 gene are associated with Aicardi-
Goutières syndrome (AGS). AGS is a monogenic autoinflammatory disorder 
that overlaps phenotypically with congenital viral infection and systemic lupus 
erythematosus (SLE), and is characterized by constitutive upregulation of type 
I interferon (IFN) in the serum and cerebrospinal fluid (33). Some children with 
AGS also display an early onset form of SLE. While SLE is associated with 
more than 20 genes, AGS is caused by autosomal recessive mutations in one 
of several genes encoding enzymes involved in nucleic acid metabolism 
(TREX1, RNASEH2, ADAR and SAMHD1) or by gain-of-function mutations in 
the cytosolic RNA sensor IFIH1 (32, 34-38). Given that the pathology of SLE is 
complex and heterogeneous, AGS could be an excellent model disease to 
study systemic autoimmunity and provide a clue to the pathogenesis of SLE. 
Considering that all of the AGS-related genes associated with nucleic acid 
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metabolism and nucleic acid sensing dysfunction implicated in autoimmunity, 
the elevated IFN signature observed in SAMHD1-related AGS patients might 
be caused by activation of the innate immune response against dysregulated 
endogenous nucleic acids. Even though SAMHD1 possesses dual enzymatic 
activities, the physiological function of SAMHD1 under natural conditions 
remains poorly understood. Therefore, the mechanism by which the mutations 
in SAMHD1 cause AGS needs to be revealed.
16
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Figure 3. Proposed mechanism of AGS pathogenesis
Lack of Trex1 or RNaseH2 activity induces the accumulation of ssDNA or 
RNA:DNA hybrids in cytoplasm, respectively. The augmented pool of DNA or 
RNA: DNA hybrids in cytoplasm leads to the activation of nucleic acid sensor 
cGAS. The defect of RNA editing by ADAR1 induces aberrant IFN response to 
dsRNA in RIG-I and MDA5 dependent manner. The mutant MDA5 lacked 
RNA-specific responsiveness also increase type I IFN response by itself. 
SAMHD1 is proposed to affect the amount of dNTP for DNA synthesis and 
impair nucleic acid homeostasis. However, it is not clearly identified.
MATERIALS AND METHODS
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1. Generation of knockout cell lines 
Wild-type and mutants of SAMHD1 were amplified by PCR from previously 
described plasmids (12) and inserted into the EGFP-N3 vector. SAMHD1-
deficient THP-1, HEK239T and HeLa cells were generated using the 
CRISPR/Cas9 system. The SAMHD1/AKT double knockout THP-1 cell line 
was established by transfecting SAMHD1-deficient THP-1 cells with single 
guide RNAs (sgRNAs) specific for AKT1. Immunoblotting and genomic DNA 
sequencing confirmed all the knockout cell lines. Guide RNA sequences of 
SAMHD1 and AKT1 are listed in Table 1. 
20
Table 1. sgRNA sequence for the generation of SAMHD1 and AKT1
knockout cell lines
21
2. Cells and human blood cell isolation
THP-1 was cultured in Roswell Park Memorial Institute (RPMI) 1640 
supplemented with 10 % fetal bovine serum (FBS), 2 mM GlutaMAX-I, and 1 % 
penicillin/streptomycin. 293T cells were maintained in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10 % FBS, 2 mM GlutaMAX-I, 
and 1 % penicillin/streptomycin. PBMCs were isolated from human blood of 
healthy donors using SepMate, according to the manufacturer’s instruction 
(Stemcell). Isolated PBMCs were transfected with SAMHD1 specific siRNA or 
control non-specific siRNA for two cycles to obtain efficient knockdown and 
incubated in RPMI media. After 48 h of incubation, PBMCs were analyzed by 
western blotting analysis to monitor the activation of STAT1 and AKT.
3. Reagents and antibodies
The chemical reagents and antibodies used in this study were purchased from 
the following manufacturers: poly (I:C) and poly (dA:dT), Sigma; T4 
Polynucleotide Kinase and T4 RNA ligase, Takara; T4 RNA Ligase 2 (truncated 
K227Q) and Antarctic Phosphatase, New England Biolabs (NEB); wortmannin 
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and rapamycin, Sigma; MK-2206, A-674563, and Lapatinib, Selleckchem;
Ruxolitinib, Invivogen; mouse monoclonal antibodies to IFNAR1 (Millipore) and 
SAMHD1 (OriGene); rabbit monoclonal antibodies to IRF3 pho-S386 (Abcam), 
RIG-I, STING, MyD88, TBK1, TBK1 pho-S172, Stat1 pho-Y701, and GSK-3β 
(all from Cell Signaling Technology); rabbit polyclonal antibodies to IRF3 
(Santa Cruz), SAMHD1 (for immunoprecipitation, Bethyl Lab), GAPDH (Ab 
Frontier), MAVS, TRIF, IRF7, STAT1, Akt, Akt pho-S473, and GSK-3β pho-S9 
(all from Cell Signaling Technology); goat polyclonal antibody to hIL-10Rb 
(R&D systems)
4. RNA interference and transfection
All siRNAs were purchased from Dharmacon as ON-Target plus. THP-1 cells 
were transfected by electroporation with indicated gene-specific siRNAs or 
non-specific siRNAs using Neon (Invitrogen). Lysates were collected 72 h after 
transfection for western blotting and qRT-PCR analysis. For nucleic acid 
stimulation, PMA-differentiated THP-1 cells were transfected with 5 μg/ml of 
poly (I:C), poly (dA:dT), or isolated DNA or RNA, using Lipofectamine 2000 
transfection reagent (Invitrogen) and undifferentiated THP-1 cells were 
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transfected by electroporation with 10 μg/ml of isolated RNA using Neon. Cells 
were harvested 4 h post transfection, followed by RNA isolation. For 
reconstitution of SAMHD1-deficient THP-1, THP-1 cells were transfected by 
electroporation with expression vectors for wild-type or mutant SAMHD1 using 
Neon. Isolated PBMCs were transfected using Interferin™ transfection reagent 
(Polyplus-transfection Inc.), according to the manufacturer’s instructions.
5. Genomic DNA and RNA preparation
Genomic DNA was purified using a Blood Mini Kit (Qiagen). Total RNA was 
isolated using the TRIzol reagent (Invitrogen). Fractionation and extraction of 
small and large RNAs were performed using the NucleoSpin miRNA system 
(Macherey-Nagel). Separation and purification of cytoplasmic and nuclear 
RNAs were carried out using a Cytoplasmic & Nuclear RNA purification kit 
(Norgen). All the purification steps were processed according to the 
manufacturers’ instructions. 
6. Quantitative real-time reverse transcription PCR
24
Total RNA was subjected to cDNA synthesis using the ReverTra Ace qPCR RT 
Kit (TOYOBO), according to the manufacturer’s instructions. The expression 
levels of various genes were measured using the iCycler iQ real-time PCR 
detection system (BioRad) using the TOPreal qPCR PreMIX (Enzynomics). 
The data were normalized to the expression level of β-actin or GAPDH. The 
primer sets used are listed in Table 2.
25
Table 2. Primer sequences used for mRNA expression
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7. Cell cycle analysis
Wild-type or SAMHD1-deficient THP-1 cells were incubated in varying serum 
concentration. After 48 h, cells were harvested and washed twice with PBS. 
Then the cells were fixed with 70% cold ethanol overnight at 4°C, followed by 
washing twice with PBS. The cells were then resuspended with 0.5 ml PBS 
and 5 µl of 20 mg/ml RNase A and 10 µl of 1 mg/ml PI solution were add, 
followed by analysis on BD FACSCanto II (BD Biosciences)
8. In vitro nuclease assay by immunoprecipitation
Pelleted THP-1 cells were lysed for 30 min at 4 °C in lysis buffer (25 mM Tris-
HCl, pH 7.5, 100 mM KCl, 1 mM DTT, 2 mM EDTA, 0.5 mM PMSF, 0.05 % NP-
40, RNase inhibitor). After sonication, the lysates were centrifuged for 30 min 
at 13,000 × g at 4 °C. anti-SAMHD1 and anti-rabbit IgG antibodies were 
incubated with Dynabeads for 1 h at room temperature. The conjugated beads 
were washed sequentially twice each with buffer A (500 mM NaCl, 10 mM Tris-
HCl, pH 7.5, 0.05 % NP-40, RNase inhibitor) and buffer B (150 mM NaCl, 10 
mM Tris-HCl, pH 7.5, 0.05 % NP-40, RNase inhibitor). Cell lysates were 
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incubated with the prepared conjugated Dynabeads for 1 h at 4 °C. The 
immunoprecipitates were washed five times with buffer B, followed by an in 
vitro nuclease assay. The in vitro nuclease assay was performed as described 
previously (12). In brief, immunoprecipitated proteins were incubated in 20 µl 
reaction mixtures containing phosphate-buffered saline (PBS) supplemented 
with 5 mM MgCl2, 2 mM dithiothreitol (DTT) and [γ-32P]-labeled RNA substrate 
(A20) at 37 °C for 30 min. The reactions were stopped by the addition of 20 µl 
of 2× RNA loading buffer and then boiled at 95 °C for 5 min. RNA was 
separated on 8 M urea/15 % polyacrylamide gels and analyzed using a BAS-
2500 phosphorimager (Fujifilm).
9. CLIP-seq and RNA-seq
CLIP-seq and RNA-seq was performed as previously described (39), with 
some modifications. Briefly, THP-1 cells were irradiated by 254nm UV at total 
600 mJ/cm2 for RNA-protein cross-liking (Spectroline) for SAMHD1-CLIP. The 
RNAs bound to SAMHD1 were immunoprecipitated with anti-SAMHD1 
conjugated beads. After ligation with 3′ adaptors 
(5′/rApp/TGGAATTCTCGGGTGCCAAG G/ddC/-3′, Integrated DNA 
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Technologies) using T4 RNA Ligase 2, truncated K227Q (NEB), RNAs were 
labeled with [γ-32P]ATP by T4 polynucleotide kinase (Takara). The RNA-
protein complex was separated by SDS-PAGE electrophoresis, then 
transferred onto nitrocellulose membrane (Whatman). The membrane with 
RNAs was cut by a razor and RNAs were extracted by phenol/chloroform 
(Ambion), followed by ethanol precipitation for RNA isolation. 5′ adaptors (5′-
GrGrUrUrCrArGrArGrUrUrCrUrArCrArGrUrCrCrGrArCrGrA rUrC-3′, Integrated 
DNA Technologies) were ligated using T4 RNA ligase (Takara). For RNA-seq, 
total RNA was extracted from wild-type and SAMHD1-deficient THP-1 cells 
using the TRIzol reagent (Invitrogen), according to the manufacturer’s 
instructions. Ribosomal RNA was removed from the total RNA using a Ribo-
Zero rRNA removal Kit (Epicentre). After RNA fragmentation by RNA 
fragmentation reagents (Ambion), RNAs of 30–60 nucleotides were purified 
and ligated with 3′ and 5′ adaptors using T4 RNA Ligase 2, truncated K227Q, 
and T4 RNA ligase, respectively. 5′ and 3′ adaptor ligated RNAs were reverse 
transcribed by using the RNA RT primer (RTP; 5′-GCCTTGGCACCCGAG
AATTCCA-3′, Integrated DNA Technologies). PCR was performed to generate 
libraries for high throughput sequencing with the 5′ end Illumina RNA PCR 
Primer (RP1) and the 3′ end Illumina RNA PCR Primer with index sequences 
(Index 1 – 9). Sequencing was performed on a HiSeq 2000/2500 (Illumina).
29
10. Bioinformatics
For preprocessing, I removed adapter sequences and low-quality ends from 
CLIP-seq and RNA- seq reads by using Cutadapt version 1.10 with -m 17 --
match-read-wildcards -O 10 -e 0.1 -q 30,30 -g AATGATACGGCGACCACCGA
GATCTACACGTTCAGAGTTCTACAGTCCGACGATC –a 
TGGAATTCTCGGGT GCCAAGGAACTCCAGTCAC options. Artifact reads 
were eliminated by the fastx_artifacts_filter command in FASTX-Toolkit 
(http://hannonlab.cshl.edu/ fastx_toolkit/) version 0.0.13.2. I also discarded 
reads mapped to human rRNA or tRNA by Bowtie2 version 2.2.7 with -t - k 2 --
very-sensitive options. Tophat version 2.1.1 with --no-coverage-search --b2-
very-sensitive (--b2- score-min L, -0.6, -0.9 only for CLIP-seq due to the high 
error rate) options was used to align these preprocessed sequencing reads 
against the human reference genome (GRCh37.p13) downloaded from the 
Reference Sequence (RefSeq) collection. In this alignment process, I also 
considered repetitive elements defined by the output of RepeatMasker that 
was downloadable from RefSeq. Based on these alignments, I calculated the 
read counts for each genomic position by using in- house software that 
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uniformly divided each multi-mapped read to all of the positions it maps to. As 
previously described (39), I applied Fisher’s exact test to detect significant 
peaks (CLIP-seq enriched regions over RNA-seq). One modification in this 
study was that I calculated p-values for every genomic position in the whole 
genome background. Then, the p-values were adjusted by qvalue package in 
R.
RSEM (40) version 1.2.30 was used to align sequencing reads against all 
transcripts of the human reference genome (GRCh37.p13) downloaded from 
the Reference Sequence (RefSeq) collection and estimate gene-level 
transcript abundances. DEGs were assessed by limma package in R (41). I
first filtered genes with total read counts less than 12 for 6 samples (i.e., 3 
replicates of wild-type and 3 replicates of SAMHD1 knockout cells). I applied 
trimmed mean of M values (TMM) normalization to read counts for the 
estimation of scale factors among samples. Then, the voom transformation 
was applied to the filtered and normalized counts. After this, the usual limma 
procedure for differential expression analysis was followed. That is, I estimated 
the fold changes and standard errors by fitting a linear model for each gene 
and applied empirical Bayes smoothing to the standard errors. Finally, 
moderated t-statistics and corresponding p-values were computed. Benjamini-
Hochberg method was used to adjust p-values for multiple testing.
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11. Ethical statement
Human blood samples were anonymously provided by the Blood Center of the 
Korean Red Cross, Seoul, under the approval of the Institutional Review Board 
of Korean Red Cross with consent for research use. Experiments involving 
human blood were approved by the Institutional Review Board at Seoul 
National University (SNUIRB No. E1512/001-004). All experiments were 
performed in accordance with Seoul National University guidelines.
12. Statistical analysis
Statistical analyses were carried out using GraphPad Prism version 5.0 
software. Statistical significance was determined by two-tailed Student’s t-tests 
(*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ns: not significant)
RESULTS
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1. SAMHD1-deficient human monocytic cells display a 
heightened IFN signature
AGS is a type of systemic inflammatory disease that has a type I IFN signature 
in human. However, Samhd1-deficient mice displayed neither significant 
upregulation of IFN-stimulated genes (ISGs) in their sera nor other systemic 
autoimmune phenotypes, although Samhd1-/- mouse cells exhibited 
spontaneous induction of ISGs (42, 43). Therefore, I used human THP-1 cells, 
a well-established model of human monocytes, to study the molecular 
pathology of the SAMHD1-related AGS. I analyzed transcriptional signature of 
AGS using two independent SAMHD1-deficient THP-1 cells engineered by 
different clustered regularly interspaced short palindromic repeats (CRISPR) 
single guide RNAs (sgRNAs). Type I interferons including various subtypes of 
IFN-α and IFN-β, and ISGs (IFITM1, CXCL10, OASL and MxA) were 
upregulated in SAMHD1-deficient cells (Figure 4A and 4B), which was largely 
consistent with the results obtained from the samples of patients with AGS (44). 
Notably, the level of tumor necrosis factor alpha (TNF-α) was similar between 
SAMHD1-deficient and wild-type cells (Figure 4A), suggesting that SAMHD1 is 
not involved in the nuclear factor-kappa B (NF-kB) pathway. The transcriptional 
induction of type I IFNs resulted in increased synthesis of type I IFN proteins in 
SAMHD1-deficient cells, as assessed by enzyme-linked immunosorbent 

































































































































Figure 4. Knockout of SAMHD1 activates an immune response in human 
monocytic cells
(A, B) Relative mRNA levels for the indicated genes in wild-type and SAMHD1-
deficient cells, as assessed by qRT-PCR and normalized to β-actin expression. 
In A and B, data represent the mean ± SEM of triplicate independent 
experiments (∗∗p ≤ 0.01, ∗∗∗p ≤ 0.001, ns: not significant, two-tailed Student's 
t-test).
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Figure 5. Knockout of SAMHD1 induces type I IFN production in human 
monocytic cells
ELISA of IFN-α production in cell extracts. ELISA of IFN-β production in 

































differentiation of THP-1 cells on the type I IFN signaling in SAMHD1-deficiency, 
I compared the expressions of type I IFN and ISGs in phorbol 12-myristate 13-
acetate (PMA)-differentiated SAMHD1-deficient cells to those in PMA-
differentiated wild-type cells (Figure 6). Interestingly, differentiated THP-1 cells 
did not show a distinct IFN signature in spite of SAMHD1-deficiency, proposing 
that SAMHD1 related type I IFN response would be differentially displayed in 
cell type specific manner. Primary fibroblasts from SAMHD1-related AGS 
patients exhibited reduced proliferation and a delay in cell cycle progression
(45). In agreement with this observation, SAMHD1-deficient THP-1 cells also 
displayed delayed cell cycle progression (Figure 7). To assess the relation of 
type I IFN response with a delayed cell cycle progression in SAMHD1-deficient 
cells, I regulated the cell cycle progression by alternating the serum 
concentration in culture media (46) (Figure 8). Low serum conditioning could 
not induce a distinct IFN signature in both wild-type and SAMHD1-deficient 
cells (Figure 9), suggesting that cell cycle delay do not explain the autoimmune 
phenotypes in SAMHD1-deficient cells.
I then performed RNA sequencing (RNA-seq) to ascertain the IFN 
signatures of AGS. SAMHD1-deficient cells showed distinct mRNA expression 
patterns among more than 1200 genes (Figure 10). Pathway enrichment 
analysis revealed that the upregulated genes were associated significantly with 
the immune system, IFN signaling, and cytokine signaling pathways (Figure 
11). Upstream regulator analysis predicted that various cytokines and
38
Figure 6. Differentiated THP-1 cells do not show a distinct IFN signature 
in SAMHD1-deficiency
qRT-PCR analysis of IFN-α, IFN-β, IFITM1 and MxA in PMA-differentiated wild-
type and SAMHD1-deficient THP-1 cells. Data were standardized to β-actin. 
Data represent the mean ± SEM of triplicate independent experiments (ns: not 












































Figure 7. The effect of SAMHD1-deficiency on cell cycle distribution
Wild-type and SAMHD1-deficient cells were synchronized by serum starvation 
for 24 h, followed by the addition of serum for 24 h to induce cell cycle re-entry. 
Cells were harvested for propidium iodide staining and analyzed by FACS to 
































































































Figure 8. The effect of changes in serum concentration on the 
manipulation of cell cycle
(A, B) Wild-type and SAMHD1-deficient THP-1 cells were incubated in 
complete media containing 10 % FBS or reduced-serum media containing 4 % 
or 2 % FBS for 48 h, followed propidium iodide staining and FACS analysis to 







































































































Figure 9. The manipulation of cell cycle is not responsible for the 
autoimmune phenotypes in SAMHD1-deficient cells
Wild-type and SAMHD1-deficient THP-1 cells were incubated in basal media 
containing 10 % FBS or reduced-serum media containing 4 % or 2 % FBS for 
48 h, followed by qRT-PCR analysis of IFITM1 and MxA mRNA levels. Data 
were standardized to β-actin. Data represent the mean ± SEM of triplicate 
independent experiments (ns: not significant, two-tailed Student's t-test).
44
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Figure 10. Identification of DEGs in SAMHD1-deficient THP-1 cells
RNA-seq MAplot of wild-type versus SAMHD1 knockout cells as indicated. 
Three biological replicates were analyzed for both data sets. Average gene 
expression is plotted on the x-axis and log2 fold-change is plotted on the y-axis; 
red dots: upregulated genes (log2 FC≥1 and adjusted p-values<0.01), green 




Figure 11. Classification of DEGs in SAMHD1-deficient THP-1 cells
Statistically significant signaling pathways for genes upregulated by over 2-fold 
in SAMHD1 knockout samples were obtained by Ingenuity Pathway Analysis 
(IPA). Blue bars indicate the ratio of the total number of genes involved in the 
specific pathway versus input list genes, while the orange squares show –log 
(p-value).
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transcription regulators related to the induction of type I IFN and ISGs would be
activated (Figure 12). In particular, a broad range of ISGs were upregulated in 
SAMHD1-deficient cells (Figure 13), which closely resembled the IFN signature 
observed for patients with SLE and AGS (44). The expressions of several ISGs 
were validated by quantitative real-time reverse transcription polymerase chain 
reaction (qRT-PCR) (Figure 14). These results indicated that SAMHD1-
deficient THP-1 cells show spontaneous autoimmune phenotypes.
2. RNA enriched in the absence of SAMHD1 is a major 
source of the IFN-a response
I examined whether inappropriate accumulation of nucleic acids in SAMHD1-
deficient cells activates IFN responses. I isolated both DNA and RNA from wild-
type and SAMHD1-deficient cells and examined their abilities to stimulate the 
IFN response in PMA-differentiated THP-1 cells. Interestingly, only RNA 
derived from SAMHD1-deficient cells, but not that from wild-type cells, highly 
activated IFN-α expression. On the other hand, DNA isolated from wild-type 
and SAMHD1-deficient cells had comparable abilities to activate IFN-α
expression (Figure 15A). RNA purified from SAMHD1-deficient cells had no 
discernible impact on the expression of IFN-β and IFITM1 mRNA compared 
with RNA from wild-type cells (Figure 15B and 15C). Considering that the 
isolated RNAs are likely composed of various RNA species, the IFN-β
49
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Figure 12. Bioinformatic prediction of the upstream regulators of DEGs in 
SAMHD1-deficient THP-1 cells
Bioinformatic analysis with IPA were performed to identify the upstream 
regulators of transcriptional regulation. Upstream regulator analysis in IPA 
sorted out type I IFN and IFN signature associated transcription regulators.
51
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Figure 13. IFN signature in SAMHD1-deficient THP-1 cells
Heatmap of ISGs expressed in the indicated cells with the RNA-seq data. 
Gene expression levels (averaged reads per kilobase per million mapped 
reads (RPKM) values over 3 replicates) was standardized and clustered based 
on the dissimilarity values (1-Pearson correlation) between genes using the 
average linkage method as shown in the dendrogram.
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Figure 14. Verification of IFN signature in SAMHD1-deficient THP-1 cells
The mRNA levels of ISG genes in wild-type and SAMHD1-deficient THP-1 cells 
were determined by qRT-PCR. Data were normalized to the GAPDH level. 
Data represent the mean ± SEM of triplicate independent experiments (∗p ≤ 



































































































































































































































Figure 15. Accumulated RNAs in SAMHD1-deficient cells function as 
immune stimuli
(A-C) PMA-differentiated wild-type THP-1 cells were stimulated with poly dA:dT, 
poly I:C, an equal amount (5 μg/ml) of isolated total DNA and RNA from wild-
type and SAMHD1-deficient cells, or left unstimulated. The mRNA levels of 
IFN-α, IFN-β and IFITM1 were determined by qRT-PCR. Data were normalized 
to β-actin expression. Data represent the mean ± SEM of triplicate independent 
experiments (∗∗∗p ≤ 0.001 two-tailed Student's t-test).
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induction by RNA species that activate retinoic acid-inducible gene-I (RIG-I) or
melanoma differentiation associated gene 5 (MDA5)-dependent pathways 
could mask the IFN-β induction by RNA substrates of SAMHD1. To investigate 
the detailed features of IFN-stimulatory RNA species, I isolated small (<200 nt) 
and large (>200 nt) RNAs in two separate fractions from each of the wild-type 
and SAMHD1-deficient THP-1 cell lines and then stimulated PMA-differentiated 
THP-1 cells with these RNAs. The large RNAs (>200 nt) from SAMHD1-
deficient cells activated IFN-α mRNA expression significantly (Figure 16A) and 
showed similar effects on the induction of IFN-b or IL-6 mRNA compared with 
the large RNAs (>200 nt) from wild-type cells (Figure 16B and 16C). Cell 
fractionation experiments also revealed that the cytoplasmic, but not the 
nuclear, RNA of SAMHD1-deficient cells induced IFN-α expression dominantly 
(Figure 17). My data suggested that the cytoplasmic RNA (>200 nt) 
accumulated in the absence of SAMHD1 triggers the IFN response. To 
investigate the discrepancy of type I IFN response in the absence of SAMHD1 
between undifferentiated and differentiated THP-1 cells, I repeated the 
experiment for RNA stimulation with RNA isolated from differentiated wild-type 
and SAMHD1-deficient THP-1 cells. These RNAs did not show significant 
differences in activating type I IFN response (Figure 18), suggesting that the 
expression and accumulation of RNA substrates of SAMHD1 are differentially 















































































































Figure 16. Large RNAs in SAMHD1-deficient cells function as immune 
stimuli
(A-C) Total RNA isolated from wild-type and SAMHD1-deficient cells were
further size-fractionated and an equal amount of RNA from each fraction was 
used to stimulate PMA-differentiated wild-type THP-1 cells, followed by qRT-
PCR analysis of IFN-α, IFN-β and IL6 mRNA levels. Data were normalized to 
β-actin expression. These data represent the mean ± SEM of triplicate 



































































































Figure 17. Cytoplasmic RNA from SAMHD1-deficient cells activates a type 
I IFN response
(A) qRT-PCR analysis of IFN-α and IFN-β expression in wild-type THP-1 cells 
stimulated with the nuclear or cytoplasmic RNA purified from wild-type and 
SAMHD1-deficient cells. Data represent the mean ± SEM of triplicate 
independent experiments (∗∗p ≤ 0.01, ns: not significant, two-tailed Student's t-
test). (B) RNA recovered from nuclear and cytoplasmic fractions was converted 
into cDNA. The cDNA was used for PCR amplification of U6 and GAPDH. U6
and GAPDH were used as markers for the quality of the fractionation.
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Figure 18. RNA from PMA-differentiated SAMHD1-deficient cells do not 
induce distinct IFN-α expression
PMA-differentiated wild-type THP-1 cells were stimulated with 5 μg/ml of RNA 
isolated from PMA-differentiated wild-type and SAMHD1-deficient cells, or left 
unstimulated. The mRNA levels of IFN-α and IFN-β were determined by qRT-
PCR. Data represent the mean ± SEM of triplicate independent experiments 
(ns: not significant, two-tailed Student's t-test).
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cause the cell type specificity of SAMHD1 related autoimmune response. 
Furthermore, I performed the RNA stimulation with RNA purified from 
undifferentiated wild-type and SAMHD1-deficient cells into undifferentiated 
wild-type or SAMHD1-deficient cells. Consistent with the data with 
differentiated THP-1 cells, RNA derived from SAMHD1-deficient cells distinctly 
activated IFN-α expression (Figure 19A and 19B). The activation of IFN 
response in undifferentiated cells was relatively mild compared to that of 
differentiated THP-1 cells. However, RNAs isolated from SAMHD1-deficient 
cells activated IFN-α expression about 3-fold higher than the RNAs isolated 
from wild-type cells in both undifferentiated wild-type and SAMHD1-deficient 
THP-1 cells. Thus, it seems that SAMHD1 could not efficiently degrade the 
transfected RNA, even though SAMHD1 degrades endogenous RNA species 
via its RNase activity.
SAMHD1 possesses both dNTPase and RNase activity, both of which are 
relevant to nucleic acid metabolism. I examined which of the two SAMHD1 
functions is involved in the regulation of the type I IFN response. The RNase 
activity of SAMHD1 in undifferentiated THP-1 cells has not been characterized.
Therefore, I first examined whether the SAMHD1 protein immunopurified from 
undifferentiated THP-1 cells possesses RNase activity. Immunopurified 
SAMHD1 protein was able to digest single-stranded RNA efficiently (Figure
20A). To exclude the possibility that contaminated RNA exonuclease during 





Figure 19. RNA from SAMHD1-deficient cells activates a type I IFN 
response
Undifferentiated wild-type (A) or SAMHD1-deficient THP-1 cells (B) were 
stimulated with 10 μg/ml of RNA isolated from undifferentiated wild-type and 
SAMHD1-deficient cells, or left unstimulated. The mRNA levels of IFN-α and 
IFN-β were determined by qRT-PCR. Data represent the mean ± SEM of 





Figure 20. SAMHD1 protein immunopurified from undifferentiated THP-1 
cells possesses RNase activity
(A, B) In vitro RNase activity assay for SAMHD1 immunopurified from 
undifferentiated THP-1 cells using A20 single-stranded RNA substrates. An 
isotype-matched control anti-IgG and anti-SAMHD1 antibodies were used for 
immunopurification. THP1 cells were infected with serial dilution of Vpx-loaded 
or control SIV VLPs (B).
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added Vpx-mediated SAMHD1 depleted controls (Figure 20B). Vpx-mediated 
degradation of SAMHD1 significantly reduced the enzymatic activity of
immunopurified SAMHD1 protein, suggesting that SAMHD1 possesses RNase 
activity in undifferentiated THP-1 cells. Previously, my colleagues identified 
SAMHD1 point mutations that caused loss of one or both functions; RNase-
/dNTPase- SAMHD1D207N, RNase
+/dNTPase- SAMHD1D137N and RNase
-
/dNTPase+ SAMHD1Q548A (12). I reconstituted SAMHD1-deficient THP-1 cells 
with these SAMHD1 mutants using transient transfection and monitored the 
expression of IFN-α mRNA. SAMHD1D207N and SAMHD1Q548A, which have no 
RNase activity, did not repress the IFN-a induction. Notably, wild-type 
SAMHD1 and SAMHD1D137N reduced the expression of IFN-a to the level 
observed in the mock control cells (Figure 21). These data supported the view 
that in SAMHD1-deficient cells, accumulation of incompletely digested RNAs 
leads to the activation of IFN response.
To gain the insight into the nature of cellular immune stimulatory RNA, I
performed high-throughput sequencing of RNA isolated by crosslinking 
immunoprecipitation (HITS-CLIP) analysis with SAMHD1. Immunoprecipitates 
of SAMHD1 protein and SAMHD1-RNA complex were successfully detected by 
western blot and autoradiography (Figure 22A). A total of 5,500,000 peaks 
covering 38,000 genes including endogenous retroelements were called 





Figure 21. RNase activity of SAMHD1 is involved in the regulation of IFN 
response
(A) Enzymatic activity of SAMHD1 wild-type and mutants (B) qRT-PCR 
analysis of IFN-α in wild-type and SAMHD1-deficient cells reconstituted with 
indicated SAMHD1 wild-type and mutant constructs. Data were normalized to 
β-actin expression. In (B), this data represents the mean ± SEM of triplicate 






Figure 22. SAMHD1 CLIP-seq
(A) Autoradiography of SAMHD1-RNA complex and western blotting of 
SAMHD1 protein immunoprecipitated from SAMHD1 CLIP. (B) Pie chart 
showing the distribution of statistically significant peaks (q<0.001) among the 
indicated RNA classes.
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region, suggesting that SAMHD1 would function in nucleus during RNA 
processing or regulate RNA debris originated from intron in cytoplasm. 11 % of
peaks were mapped to 3¢ UTR and only 8 % of peaks were mapped to 5¢ UTR 
and CDS region (Figure 22B). Notably, 18 % were repetitive elements that 
have been suggested as the source of endogenous immune stimulatory 
nucleic acid to account for AGS. My data showed that significant portion of the 
retroelement RNAs that are identified in SAMHD1 CLIP-seq were upregulated 
in SAMHD1-deficient cells. I, thus, speculate that these retroelement RNAs 
could be the substrates of SAMHD1 and function as immune stimulatory RNAs 
in SAMHD1-deficient cells.
3. ISG activation in SAMHD1-deficient cells is dependent 
on IRF3 & Type I IFN receptor
I sought to identify the RNA sensing pathway associated with ISG induction in 
SAMHD1-deficient cells. RIG-I-like receptors (RLRs), which include RIG-I and
MDA5, and intracellular Toll-like receptors (TLRs) are well known cytosolic 
RNA sensors (49-52). I assumed that one of these RNA sensors might be 
linked to the IFN signature in SAMHD1-deficient cells. Therefore, I depleted 
each of these sensors or downstream molecules independently using short 
interfering RNA (siRNA) treatment (Figure 23). All of the known RNA sensors 
and intermediate signaling molecules, except Interferon Regulatory Factor 3 
74
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Figure 23. Depletion of nucleic acid sensors or downstream molecules 
using siRNA treatment
Wild-type and SAMHD1-deficient THP-1 cells were transfected with control 
siRNA or specific siRNA for the indicated genes for 72 h. Cell lysates were 










































































































































Figure 24. IRF3 is indispensable for ISGs induction in SAMHD1-
deficiency
Wild-type and SAMHD1-deficient THP-1 cells were transfected with control 
siRNA or specific siRNA for the indicated genes for 72 h. The cellular mRNA 
was analyzed by qRT-PCR to determine the expression of IFITM1 and MxA
relative to GAPDH. These data represent the mean ± SEM of triplicate 
independent experiments. (∗∗p ≤ 0.01, two-tailed Student's t-test).
78
(IRF3), were dispensable for the spontaneous IFN signature in SAMHD1-
deficient cells (Figure 24). IRF3 depletion in SAMHD1-deficient cells abrogated 
the expression of IFITM1 and MxA to near the levels of wild-type THP-1 cells. 
Activation of almost known RNA sensing pathways requires the 
phosphorylation of TBK1, which acts upstream of IRF3. Notably, 
phosphorylated TBK1 levels were similar between wild-type and SAMHD1-
deficient cells (Figure 23), suggesting that a novel RNA sensing pathway is 
responsible for the IFN response observed in SAMHD1-deficient cells.
To investigate whether the proteins secreted from SAMHD1-deficient cells 
boost ISG induction, I harvested the conditioned media from wild-type and 
SAMHD1-deficient THP-1 cells. The conditioned media from both wild-type and 
SAMHD1-deficient cells did not exhibit any significant differential ability to 
stimulate IFN-a expression. However, wild-type THP-1 cells treated with the 
conditioned media from SAMHD1-deficient cells displayed significantly 
elevated ISG levels in a time-dependent manner (Figure 25). Both type I (IFN-
a and IFN-b) and type III (IFN-l) IFNs can lead to the similar spectrum of ISG 
induction. To identify the discrete contribution of type I and type III IFNs to ISG 
induction, SAMHD1-deficient cells were treated with neutralizing antibodies 
directed against the type I and III IFN receptor subunits, IFNAR1 and IL10Rβ, 
respectively. Neither the anti-IFNAR1 nor anti-IL10Rβ antibodies reduced the 
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Figure 25. Secreted proteins from SAMHD1-deficient cells elevate ISG 
levels in a time-dependent manner
qRT-PCR analysis of IFN-α and MxA in THP-1 cells incubated with conditioned 
media (Cond. Media.) from wild-type or SAMHD1-deficient cells for the 
indicated days. Data were standardized to GAPDH. Data represent the mean ± 
SEM of triplicate independent experiments. (∗∗p ≤ 0.01, ∗∗∗p ≤ 0.001, two-
tailed Student's t-test).
81
of ISGs (IFITM1 and MxA) were reduced to basal levels in cells treated with 
anti-IFNAR1, but not in those treated with the anti-IL10Rβ antibody. Co-
treatment with both IFNAR1 and IL10Rβ antibodies did not show synergistic 
inhibitory effects on ISGs induction (Figure 26). Thus, I concluded that type I 
IFN is responsible for the IFN signature observed in SAMHD1-deficient cells. 
Type I IFN receptors associate with Janus activated kinases (JAKs), and 
activation of the Janus kinase/signal transducers and activators of transcription 
(JAK/STAT) pathway is indispensable for ISGs induction (53). JAK inhibitor 
treatment diminished ISG induction thoroughly (Figure 27). Taken together, 
these findings indicated that the type I IFN secreted by the IRF3-dependent 
novel RNA sensing pathway activates ISG induction, which could be 
responsible for AGS pathogenesis.
4. The PI3K/AKT signaling pathway is involved in linking 
SAMHD1-deficiency to the IFN response
Type I IFN can activate multiple signaling pathways, including the JAK/STAT 
pathway, the p38 and extracellular signal-regulated kinase (ERK) pathways, 
and the phosphoinositide 3-kinase (PI3K)/AKT pathway (54). Pathway 
enrichment analysis of genes upregulated in SAMHD1-deficient cells showed a 
significant enrichment of genes related to the PI3K/AKT pathway (Figure 11). 
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Figure 26. ISGs induction in SAMHD1-deficiency occurs through type I 
IFN receptor signaling pathway
qRT-PCR analysis of IFN-α, IFN-β, IFITM1 and MxA in wild-type and 
SAMHD1-deficient THP-1 cells treated with control IgG or neutralizing 
antibodies against type I and III IFN receptor subunits as indicated. Results 
were standardized to β-actin levels. These data represent the mean ± SEM of 










































Figure 27. JAK inhibitor treatment diminishes ISG induction
The measurement of IFITM1 and MxA mRNA expressions in SAMHD1-
deficient cells by qRT-PCR after treating SAMHD1-deficient cells with control 
dimethylsulfoxide (DMSO) or 2 µM Ruxolitinib for 24 h. Data were standardized 
to GAPDH. Data represent the mean ± SEM of triplicate independent 





Figure 28. AKT is highly activated in SAMHD1-deficient cells
(A, B) Western blotting analysis of cell extracts from wild-type and two 
independent SAMHD1-deficient cell lines using the indicated antibodies. 
GAPDH served as a loading control.
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assessed by the phosphorylation levels of these molecules (Figure 28A). IRF3 
was also activated in SAMHD1-deficient cells, which agreed with the 
observation that depletion of IRF3 abrogates ISG induction (Figure 24). 
However, p38 and ERK pathways were not activated in SAMHD1-deficient 
cells (Figure 28B). To ascertain the role of the PI3K/AKT pathway in the 
SAMHD1-related IFN response, I treated SAMHD1-deficient cells with 
wortmannin, a PI3K inhibitor. Wortmannin inhibited not only the induction of 
type I IFN and ISGs but also the activation of AKT and STAT1 (Figure 29 and 
Figure 30). Treatment of SAMHD1-deficient cells with the pan-AKT inhibitor 
MK2206 or the AKT1 inhibitor A674563 reduced the IFN signature. By contrast, 
inhibition of the PI3K upstream tyrosine kinase using Lapatinib and inhibition of 
mTOR, a downstream effector of AKT, using rapamycin did not affect the IFN 
signature (Figure 31). Consistent with these data, the activation of STAT1 is 
also abrogated by AKT inhibitors treatment (Figure 32). To confirm the data 
obtained from the pharmacological studies, I generated the SAMHD1/AKT1
double knockout cells via the CRISPR/ CRISPR associated protein9 (Cas9) 
system. Phosphorylation of STAT1 and IRF3 induced by SAMHD1 knockout 
was markedly diminished upon SAMHD1/AKT1 double knockout (Figure 33). 
Type I IFN production and ISGs induction also significantly decreased in 
SAMHD1/AKT1 double knockout cells (Figure 34). Glycogen synthase kinase 
3-β (GSK3-β) regulates TLR4 mediated IFN-β production negatively (55). The 
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Figure 29. PI3K inhibitor blocks the induction of type I IFN and ISGs
qRT-PCR analysis of IFN-α, IFN-β and MxA levels in wild-type and SAMHD1-
deficient THP-1 cells treated with control DMSO or 1 µM Wortmannin for 24 h. 
Data were normalized to GAPDH levels. Data represent the mean ± SEM of 
triplicate independent experiments (∗p ≤ 0.05, two-tailed Student's t-test).
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Figure 30. PI3K inhibitor suppresses the activation of STAT1 and AKT
Wild-type and SAMHD1-deficient THP-1 cells were treated with control DMSO 
or 1 µM Wortmannin for 24 h. Cell lysates were analyzed for the western 
blotting analysis to determine the phosphorylation status of STAT1 and AKT. 













































































































































































Figure 31. AKT inhibitor diminishes the induction of type I IFN and ISGs
Wild-type and SAMHD1-deficient THP-1 cells were treated with control DMSO, 
1 µM MK2206, 1 µM A674563, 0.1 µM Lapatinib or 50 nM Rapamycin for 24 h. 
Cells were analyzed for the mRNA levels of IFN-α, IFN-β and MxA relative to 
GAPDH by qRT-PCR. Data represent the mean ± SEM of triplicate 




Figure 32. AKT inhibitor abolishes the activation of STAT1 and AKT
Wild-type and SAMHD1-deficient THP-1 cells were treated with control DMSO 
or 1 µM Wortmannin for 24 h. Cell lysates were analyzed for the western 
blotting analysis to determine the phosphorylation status of STAT1 and AKT. 
GAPDH serves as a loading control.
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Figure 33. AKT knockout abrogates the activation of IRF3 and STAT1 in 
SAMHD1-deficient cells
The phosphorylation status of STAT1 and IRF3 in wild-type, SAMHD1 knockout 
and SAMHD1/AKT double-knockout THP-1 cells was determined by western 








































































































































































































































Figure 34. AKT knockout abrogates SAMHD1-associated AGS 
phenotypes
(A, B) Determination of type I IFN and ISGs production in SAMHD1/AKT1
double knockout THP-1 cells compared with wild-type and SAMHD1 single 
knockout cells. Using independent sgRNAs (sgAKT1-1 and sgAKT1-2) 
targeting AKT1, two independent SAMHD1/AKT double knockout clones with a 
SAMHD1-null background were established and used for the experiments. 
IFN-α in cell extracts and IFN-β in supernatants were measured using an 
ELISA. ND, not detectable (A). The expression of ISGs (MxA, IFITM1, ISG15
and IFI27) in the same samples as in A was measured by qRT-PCR, 
normalized to GAPDH expression (B). Data represent the mean ± SEM of 
triplicate independent experiments (∗∗p ≤ 0.01, ∗∗∗p ≤ 0.001, two-tailed 
Student's t-test).
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deficient cells (Figure 28A). Therefore, the SAMHD1-related type I IFN 
response is likely independent of the GSK3-β pathway. The PI3K/AKT pathway 
can be also activated by type I IFN. Thus, I attempted to clarify the cause-effect 
relationship between type I IFN production and activation of the PI3K/AKT 
pathway. First, I investigated whether treatment of AKT inhibitor abolishes the 
activation of IRF3. As reported, MK2206 inhibited AKT1 phosphorylation, while 
A674563, which blocks the phosphorylation of AKT downstream targets, does 
not. Both AKT inhibitors abrogate IRF3 phosphorylation (Figure 32). 
Neutralizing antibodies against the type I IFN receptor inhibited STAT1 
phosphorylation, but not that of AKT or IRF3 (Figure 35). siRNA-mediated 
depletion of IRF3 diminished STAT1 phosphorylation, but not that of AKT 
(Figure 36), suggesting that the PI3K/AKT pathway functions upstream of IRF3 
activation in the type I IFN-producing pathway. Taken together, these results 
showed that IFN production in SAMHD1-deficient cells occurs through the 
PI3K/AKT/IRF3 signaling axis.
The phosphorylation of AKT induced by SAMHD1 knockout was 
antagonized by ectopic expression of wild-type SAMHD1 or RNase+/dNTPase-
SAMHD1D137N. Expression of the RNase-defective mutants, SAMHD1D207N and 
SAMHD1Q548A, had little effect on AKT phosphorylation (Figure 37), which was 
consistent with the observation that the RNase activity of SAMHD1 is critical to 
suppress the spontaneous IFN response in SAMHD1-deficient cells (Figure 21).
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To explore the physiological relevance of my findings, I analyzed the role
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Figure 35. The PI3K/AKT functions upstream of type I IFN receptor 
signaling pathway
Western blotting analysis of cell extracts from wild-type and SAMHD1-deficient 
cells treated with control IgG or a neutralizing antibody against a type I IFN 
receptor subunit for 48 h. GAPDH served as a loading control.
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Figure 36. The PI3K/AKT functions upstream of IRF3 to activate type I IFN 
response
Western blotting analysis of cell extracts from wild-type and SAMHD1-deficient 
cells transfected with control non-specific siRNA or a specific siRNA for IRF3. 















































Figure 37. RNase activity of SAMHD1 is responsible for the activation of 
AKT
Determination of the phosphorylation status of AKT after reconstitution of 
SAMHD1-deficient cells with wild-type and SAMHD1 mutants by western 
blotting analysis. Graph shown below indicates ratio of phosphoAKT to wild-
type control.
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for SAMHD1 in regulating an IFN response using human peripheral blood 
mononuclear cells (PBMCs). In human PBMCs, siRNA-mediated SAMHD1 
silencing elicited the activation of STAT1 and AKT, but had no effect on TBK1 
activation (Figure 38), recapitulating the phenotypes seen in SAMHD1-deficient 
THP-1 cells. By comparison, knockout of SAMHD1 in HEK293T and HeLa cells 
did not result in activation of STAT1 and AKT or the induction of ISGs (Figure 
39 and Figure 40), which suggested that the type I interferonopathy associated 
with SAMHD1-deficiency is cell type-specific. 
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Figure 38. siRNA-mediated SAMHD1 silencing in human PBMCs 
recapitulates the phenotypes seen in SAMHD1-deficient THP-1 cells
Isolated PBMCs from four donors were transfected with SAMHD1-specific 
siRNA or control non-specific siRNA for two cycles to enhance the knockdown 
efficiency. After 48 h of incubation, PBMCs were analyzed by western blotting 
to monitor the activation of STAT1 and AKT. Data are representative of four 
























































Figure 39. SAMHD1-deficient 293T cells do not display AGS phenotypes
(A, B) SAMHD1-deficient cell lines were constructed in 293T cells using the 
CRISPR/Cas9 system. Western blotting analysis of cell extracts from wild-type 
and SAMHD1-deficient 293T cells (A). Cell lysates were analyzed for the 
phosphorylation status of STAT1 and AKT with the indicated antibodies. 
GAPDH was loaded as a control. The expression of ISGs (MxA, IFITM1, 
ISG15 and IFI27) in the same samples were measured by qRT-PCR, 






















































Figure 40. SAMHD1-deficient HeLa cells do not display AGS phenotypes
(A, B) SAMHD1-deficient cell lines were constructed in HeLa cells using the 
CRISPR/Cas9 system. Western blotting analysis of cell extracts from wild-type 
and SAMHD1-deficient HeLa cells (A). Cell lysates were analyzed for the 
phosphorylation status of STAT1 and AKT with the indicated antibodies. 
GAPDH was loaded as a control. The expression of ISGs (MxA, IFITM1, 
ISG15 and IFI27) in the same samples were measured by qRT-PCR, 
normalized to GAPDH expression (B).
DISCUSSION
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SAMHD1 had been identified as HIV-1 restriction factor in the last decade and 
it was initially reported to inhibit HIV-1 replication through its dNTPase activity
(24, 25). Later my colleagues reported that SAMHD1 restricts HIV-1 and 
retroviruses through its RNase activity (12, 56). However, several studies 
reported that they have not observed the RNase activity of SAMHD1, even 
though SAMHD1 could bind nucleic acids such as ssRNA (30, 57). To clarify 
this discrepancy, my colleagues recently showed that SAMHD1 is a 
phophorolytic exoribonuclease with A or U base preference (13). Nevertheless, 
the existence of RNase activity of SAMHD1 is still being debated.
The current study identified the signaling mechanism driving the chronic 
upregulation of type I IFN in AGS related to SAMHD1-deficiency. My findings 
showed that the RNA species larger than 200 nucleotides that accumulated in 
SAMHD1-deficient cells trigger a type I IFN response. More specifically, I
observed that cytosolic RNA species larger than 200 nucleotides are 
responsible for the type I IFN induction. This type I IFN response does not 
involve any of the known signaling pathways converging on the activation of 
TBK1. Instead, the type I IFN response occurs via a novel PI3K/AKT/IRF3 
signaling pathway. Consequently, ISGs are induced in bystander cells via a 
type I IFN receptor- and JAK/STAT-dependent manner (Figure 41).
In contrast to AGS patients with mutations in SAMHD1 (32), Samhd1-
deficient mice did not exhibit any distinct clinical phenotypes (42, 43). The 
discrepancy between the mouse and human systems in terms of SAMHD1-
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Figure 41. A working model for SAMHD1-related interferonopathy in AGS
Based on the current study, we propose a working model for linking SAMHD1-
deficiency to a type I IFN response. In the absence of functional SAMHD1, 
inappropriately metabolized RNAs accumulate in cells. An unknown RNA 
sensor recognizes the accumulated RNAs and triggers the downstream 
activation of the PI3K/AKT signaling pathway, resulting in the expression of 
type I IFN through IRF3 activation. Finally, binding of type I IFN to the type I 
IFN receptors of bystander cells activates the JAK/STAT signaling pathway, 
leading to the induction of ISGs.
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related IFN responses might arise from differences in the putative nucleic acid 
substrates of SAMHD1. There are striking differences between the mouse and 
human ERVs/LTR elements in terms of their activities, tissue specific 
expression and temporal regulation during development (58, 59). Given the 
propensity of these ERVs/LTR elements to affect gene expression, the 
differences of the repertoire of ERVs/LTR elements could account for the 
differential susceptibilities of humans and mice to SAMHD1-regulated IFN 
responses. Another possibility is that an unknown RNA sensor or other 
components involved in the constitutive IFN-induced signaling pathway could 
be missing in mice. Recently, a study reported that a cGAS/STING-dependent 
IFN response is triggered in Samhd1-deficient mice, although that study did not 
address which substrates are involved in the IFN response (60). Mice contain 
“active” LTR elements and significant ERV activity (58). By contrast, “active” 
ERVs/LTR elements in humans, while present in comparable numbers, have 
not been reported (61). Thus, the reverse transcribed DNAs originating from 
the mouse ERVs/LTR elements might be a predominant source of the 
cGAS/STING-mediated IFN response. Furthermore, these disparities could 
cause the discrepancy of the source of IFN response between humans and 
mice, leading to the absence of systemic autoimmune phenotypes in Samhd1-
deficient mice compared with SAMHD1-related AGS patients.
Notably, SAMHD1 specifically targets retroviral RNA for degradation (12, 56). 
Even though SAMHD1-CLIP failed to identify dominant substrates and specific 
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binding motifs of SAMHD1, many retroelement RNAs were bound to SAMHD1. 
My RNA-seq analysis further displayed that in SAMHD1-deficient THP-1 cells, 
many endogenous retroelement RNAs, primarily LINEs and LTR elements, are 
upregulated significantly. Therefore, the accumulated retroelement-derived 
RNA transcripts could be direct substrates of SAMHD1, functioning as 
immunostimulatory RNAs to activate the type I IFN response. The fundamental 
question that still remains unanswered is which RNA sensors are involved in 
linking SAMHD1-deficiency to an IFN response. In addition, PI3K/AKT plays an 
important role in multiple signaling pathway and regulating various cellular 
function (62). AKT performs diverse tasks by controlling numerous downstream 
effectors. Therefore, downstream effector of AKT which directly activate IRF3 
needs to be identified. On the other hand, I also observed that lots of genes 
are significantly regulated by SAMHD1-deficiency in direct or indirect manner 
and various RNA species, which include small nucleolar RNAs (snoRNAs), are 
bound to SAMHD1 protein. snoRNAs are known to guide the modification (2¢-
O-methylation and pseudouridylation) of RNAs represented by rRNAs (63) and 
the incorporation of 2¢-O-methylated nucleosides or pseudouridine into RNA 
diminishes immunostimulatory activity (64, 65). Therefore, SAMHD1 would 
indirectly affect the immunostimulatory activity of endogenous RNAs by 
regulating RNA modification, accounting for a partial role for entire type I IFN 
response in SAMHD1-deficient cells. Considering the phenotypical overlap of 
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AGS with SLE, the pathology of SLE patients, in some cases, might be 
associated with the accumulation of aberrantly metabolized endogenous 
nucleic acids. A greater understanding of the pathogenesis of type I 
interferonopathies is not only of scientific interest but might lead to new 
therapies for autoinflammatory diseases.
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SAMHD1은 dNTPase와 RNase, 두 가지 효소 활성을 가지고 있는 단
백질이다. SAMHD1은 마우스의 Mg11 유전자의 이종상동성 유전자로 알려
졌지만, 대부분의 연구가 HIV-1 조절 기작과 관련되어서 진행되어왔다.
SAMHD1은 초기에 역전사에 필요한 dNTP를 분해함으로써 HIV-1의 복제를
억제하는 것으로 알려졌으나, 이후 직접 HIV-1 RNA와 결합하고 분해함으로
서 이를 조절하는 경로 또한 보고되었다.
제 1형 인터페론 신호전달 과정의 항상성이 무너지게 되면 자가면역질
환이 생성될 수 있다. AGS는 지속적인 제 1형 인터페론 신호전달과정의 활
성화를 특징으로 가지는 자가면역질환의 하나로 선천적인 바이러스 감염이
나 전신성 홍반성 루프스와 유사한 병증을 보이는 것으로 알려져 있다.
AGS 환자에게서 돌연변이가 일어나는 것으로 알려져 있는 원인 유전자들
은 대부분 핵산 대사 과정과 연관되어 있기 때문에, 대사 과정에서 적절하
게 처리되지 못한 핵산들이 세포 내부에 축적되고 나아가 지속적인 제 1형
인터페론 생성을 유도하는 것으로 추측되고 있다. TREX1, RNASEH2, 
ADAR1 그리고 IFIH1과 같은 단백질의 기능 이상으로 생겨나는 AGS에 대
해서는 상대적으로 연구가 많이 되었고, 그 작용 기작도 어느정도 보고된
바 있다. 하지만 SAMHD1의 유전적 결손을 가진 AGS 환자에게서 발생하
고 있는 지속적인 제 1형 인터페론 반응이 어떠한 메커니즘을 통해서 유도
되는지는 아직까지 정확하게 밝혀지지 않았다.
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이 연구에서 나는 SAMHD1이 결손된 사람 단핵 백혈구 세포를 만들었
고, 이 세포에서 AGS와 같은 제 1형 인터페론 반응이 나타나는 것을 관찰
하였다. 사람 단핵 백혈구 세포에 존재하는 SAMHD1은 RNase 효소 활성을
가지고 있었고, SAMHD1이 결손된 세포에서 추출한 핵산 중 RNA에 의해서
만 WT에서 추출한 핵산과 달리 유의미한 제 1형 인터페론 반응이 나타나
는 것을 확인할 수 있었다. 또한 SAMHD1이 결손된 세포에 야생형
SAMHD1과 dNTPase 혹은 RNase로서의 기능이 각각 손상된 혹은 두 가지
효소 기능이 모두 상실된 돌연변이 SAMHD1을 재구축해 봄으로써,
SAMHD1의 RNA 분해 효소 기능이 제 1형 인터페론 반응을 완화 시키는데
중요하게 작용한다는 것을 확인할 수 있었다. 이 결과는 정상적인 상황에서
SAMHD1에 의해 조절되는 내재적인 RNA 기질들이 SAMHD1이 결손됨에
따라 분해되지 못하고 세포 내부에 축적되고, 이 RNA를 면역 반응의 기질
로 이용하는 제 1형 인터페론 반응이 활성화 된다는 것을 시사한다. 또한, 
RNA-seq과 SAMHD1-CLIP seq 데이터 분석을 통해 내재적 레트로엘레먼트
에 의해서 전사된 RNA가 SAMHD1 결손에 의한 AGS를 유도하는 주요한
원인물질이 될 수 있다는 것을 예상할 수 있었다. 이러한 제 1형 인터페론
반응은 기존에 핵산 매게 반응에서 중요한 역할을 하는 것으로 잘 알려진
단백질인 TBK1에 의해서 영향을 받지 않고, 오직 IRF3의 의해서만 조절되
는 것을 확인할 수 있었다. 이러한 사실을 바탕으로 하여 나는 SAMHD1의
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결손에 의해 나타나는 제 1형 인터페론 반응은 기존에 잘 보고된 RNA 매
개 선천성 면역 반응 경로가 아니라 PI3K/AKT/IRF3를 축으로 하는 새로운
RNA 인지 경로를 통해서 유도된다는 것을 밝혔다. AKT와 IRF3는 SAMHD1
이 결손된 세포에서 강하게 인산화됨으로써 그 기능이 활성화되어 있었다.
PI3K나 AKT 단백질에 대한 억제제를 SAMHD1이 결손된 세포에 처리하였
을 경우 제 1형 인터페론 반응의 활성이 눈에 띄게 저해된다는 사실을 관
찰 할 수 있었다. 또한 유전자 조작 기술을 이용하여 SAMHD1이 결손된 세
포에서 AKT를 추가로 결손 시키거나 siRNA를 이용하여 IRF3를 결핍 시켰
을 경우에도 억제제 처리시와 동일하게 인터페론 반응이 감소되는 것을 확
인하였다. 이러한 AKT의 활성 또한 제 1형 인터페론 반응과 마찬가지로
SAMHD1의 RNase 효소 기능에 의해서 조절된다는 사실을 SAMHD1 재구
축실험을 통해서 밝혀낼 수 있었다. 사람 단핵 백혈구 세포뿐만 아니라 말
초 혈액 단핵구 세포에서도 SAMHD1 결핍에 의한 제 1형 인터페론 반응이
유도되는 것을 확인하였으나, HEK293T나 HeLa 세포에서는 이러한 결과가
나타나지 않았다. 이를 통해서 SAMHD1 결손에 의해 나타나는 제 1형 인터
페론 반응이 세포 특이적인 현상이라는 것을 확인할 수 있었다. 본 연구를
통해서 새로이 밝혀낸 AGS 관련 RNA 인지 신호전달 경로는 AGS나 그와
유사한 자가면역질환에 대한 분자생물학적 발생기전 연구에 새로운 방향성
을 제시할 뿐만 아니라 새로운 치료제 개발의 단초가 될 것으로 기대된다.
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